No connection

Search Results

PAVS vs RKDA

PAVS
Paranovus Entertainment Technology Ltd.
BEARISH
Price
$1.67
Market Cap
$1.8M
Sector
Consumer Defensive
AI Confidence
95%
RKDA
Arcadia Biosciences, Inc.
BEARISH
Price
$1.18
Market Cap
$2.4M
Sector
Consumer Defensive
AI Confidence
95%

Valuation

P/E Ratio
PAVS
--
RKDA
--
Forward P/E
PAVS
--
RKDA
-0.92
P/B Ratio
PAVS
0.05
RKDA
0.39
P/S Ratio
PAVS
0.14
RKDA
0.5
EV/EBITDA
PAVS
-7.67
RKDA
0.41

Profitability

Gross Margin
PAVS
19.97%
RKDA
36.04%
Operating Margin
PAVS
-5.06%
RKDA
-152.61%
Profit Margin
PAVS
-54.84%
RKDA
-48.15%
ROE
PAVS
-21.54%
RKDA
-45.14%
ROA
PAVS
-3.13%
RKDA
-32.71%

Growth

Revenue Growth
PAVS
18033.4%
RKDA
-25.9%
Earnings Growth
PAVS
--
RKDA
--

Financial Health

Debt/Equity
PAVS
0.11
RKDA
--
Current Ratio
PAVS
1.15
RKDA
3.09
Quick Ratio
PAVS
0.88
RKDA
2.42

Dividends

Dividend Yield
PAVS
--
RKDA
--
Payout Ratio
PAVS
0.0%
RKDA
0.0%

AI Verdict

PAVS BEARISH

PAVS exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a catastrophic price collapse of 99.9% over the last year. While the company shows a low debt-to-equity ratio and a positive gross margin, these are overshadowed by a -54.84% profit margin and a total lack of institutional analyst coverage. The extreme revenue growth figure (18,033%) appears to be a mathematical anomaly from a near-zero base rather than sustainable scaling. Given the technical trend of 0/100 and the price drop from a 52-week high of $1680 to $1.67, the asset is currently a high-risk value trap.

Strengths
Low Debt/Equity ratio (0.11)
Positive Gross Margin (19.97%)
Current Ratio above 1.0 (1.15)
Risks
Catastrophic price devaluation (-99.9% 1Y change)
Severe negative profit margins (-54.84%)
Weak financial health (Piotroski F-Score 3/9)
RKDA BEARISH

RKDA exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all health metrics. Despite a strong current ratio of 3.09 suggesting short-term liquidity, the company suffers from severe operational inefficiency with an operating margin of -152.61% and declining year-over-year revenue growth of -25.90%. The catastrophic 5-year price decline of -98.8% and a 0/100 technical trend score confirm a persistent bearish trajectory. The stock is currently a classic value trap, trading at a low Price/Book (0.39) but lacking any catalyst for recovery.

Strengths
Strong short-term liquidity (Current Ratio: 3.09)
Positive Gross Margin (36.04%) indicating product viability
Low Price-to-Book ratio (0.39) suggesting deep discount to assets
Risks
Critical fundamental health (Piotroski F-Score: 0/9)
Severe operational losses (Operating Margin: -152.61%)
Negative revenue growth (-25.90% YoY)

Compare Another Pair

PAVS vs RKDA: Head-to-Head Comparison

This page compares Paranovus Entertainment Technology Ltd. (PAVS) and Arcadia Biosciences, Inc. (RKDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile